TY - JOUR
T1 - Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021
AU - Feng, Gong
AU - Targher, Giovanni
AU - Byrne, Christopher D.
AU - Yilmaz, Yusuf
AU - Wai-Sun Wong, Vincent
AU - Adithya Lesmana, Cosmas Rinaldi
AU - Adams, Leon A.
AU - Boursier, Jerome
AU - Papatheodoridis, George
AU - el-Kassas, Mohamed
AU - Méndez-Sánchez, Nahum
AU - Sookoian, Silvia
AU - Castera, Laurent
AU - Chan, Wah-Kheong
AU - Ye, Feng
AU - Treeprasertsuk, Sombat
AU - Cortez-Pinto, Helena
AU - Yu, Hon Ho
AU - Kim, Won
AU - Romero-Gómez, Manuel
AU - Nakajima, Atsushi
AU - Win, Khin Maung
AU - Kim, Seung Up
AU - Holleboom, Adriaan G.
AU - Sebastiani, Giada
AU - Ocama, Ponsiano
AU - Ryan, John D.
AU - Lupșor-Platon, Monica
AU - Ghazinyan, Hasmik
AU - Al-Mahtab, Mamun
AU - Hamid, Saeed
AU - Perera, Nilanka
AU - Alswat, Khalid A.
AU - Pan, Qiuwei
AU - Long, Michelle T.
AU - Isakov, Vasily
AU - Mi, Man
AU - Arrese, Marco
AU - Sanyal, Arun J.
AU - Sarin, Shiv Kumar
AU - Leite, Nathalie Carvalho
AU - Valenti, Luca
AU - Newsome, Philip N.
AU - Hagström, Hannes
AU - Petta, Salvatore
AU - Yki-Järvinen, Hannele
AU - Schattenberg, J. rn M.
AU - Castellanos Fernández, Marlen I.
AU - Leclercq, Isabelle A.
AU - Aghayeva, Gulnara
AU - Elzouki, Abdel-Naser
AU - Tumi, Ali
AU - Sharara, Ala I.
AU - Labidi, Asma
AU - Sanai, Faisal M.
AU - Matar, Khaled
AU - Al-Mattooq, Maen
AU - Akroush, Maisam Waid
AU - Benazzouz, Mustapha
AU - Debzi, Nabil
AU - Alkhatry, Maryam
AU - Barakat, Salma
AU - Al-Busafi, Said A.
AU - Rwegasha, John
AU - Yang, Wah
AU - Adwoa, Agyei
AU - Opio, Christopher Kenneth
AU - Sotoudeheian, Mohammadjavad
AU - Wong, Yu Jun
AU - George, Jacob
AU - Zheng, Ming-Hua
N1 - Publisher Copyright:
© 2024 The Author(s)
PY - 2025/3/1
Y1 - 2025/3/1
N2 - Background & Aims: This study used the Global Burden of Disease data (2010–2021) to analyze the rates and trends of point prevalence, annual incidence, and years lived with disability (YLDs) for metabolic dysfunction-associated steatotic liver disease (MASLD) in 204 countries. Methods: Total numbers and age-standardized rates per 100,000 population for MASLD prevalence, annual incidence, and YLDs were compared across regions and countries by age, sex, and sociodemographic index (SDI). Smoothing spline models were used to evaluate the relationship between the burden of MASLD and SDI. Estimates were reported with uncertainty intervals (UI). Results: Globally, in 2021, the age-standardized rates per 100,000 population of point prevalence of MASLD were 15,018.1 cases (95% UI 13,756.5–16,361.4), annual incidence rates were 608.5 cases (598.8–617.7), and YLDs were 0.5 (0.3–0.8) years. MASLD point prevalence was higher in men than women (15,731.4 vs. 14,310.6 cases per 100,000 population). Prevalence peaked at ages 45–49 for men and 50–54 for women. Kuwait (32,312.2 cases per 100,000 people; 95% UI: 29,947.1–34,839.0), Egypt (31,668.8 cases per 100,000 people; 95% UI: 29,272.5–34,224.7), and Qatar (31,327.5 cases per 100,000 people; 95% UI: 29,078.5–33,790.9) had the highest prevalence rates in 2021. The largest increases in age-standardized point prevalence estimates from 2010 to 2021 were in China (16.9%, 95% UI 14.7%–18.9%), Sudan (13.3%, 95% UI 9.8%–16.7%) and India (13.2%, 95% UI 12.0%–14.4%). MASLD incidence varied with SDI, peaking at moderate SDI levels. Conclusions: MASLD is a global health concern, with the highest prevalence reported in Kuwait, Egypt, and Qatar. Raising awareness about risk factors and prevention is essential in every country, especially in China, Sudan and India, where disease incidence and prevalence are rapidly increasing. Impact and implications: This research provides a comprehensive analysis of the global burden of MASLD, highlighting its rising prevalence and incidence, particularly in countries with varying sociodemographic indices. The findings are significant for both clinicians and policymakers, as they offer critical insights into the regional disparities in MASLD burden, which can inform targeted prevention and intervention strategies. However, the study's reliance on modeling and available data suggests cautious interpretation, and further research is needed to validate these findings in clinical and real-world settings.
AB - Background & Aims: This study used the Global Burden of Disease data (2010–2021) to analyze the rates and trends of point prevalence, annual incidence, and years lived with disability (YLDs) for metabolic dysfunction-associated steatotic liver disease (MASLD) in 204 countries. Methods: Total numbers and age-standardized rates per 100,000 population for MASLD prevalence, annual incidence, and YLDs were compared across regions and countries by age, sex, and sociodemographic index (SDI). Smoothing spline models were used to evaluate the relationship between the burden of MASLD and SDI. Estimates were reported with uncertainty intervals (UI). Results: Globally, in 2021, the age-standardized rates per 100,000 population of point prevalence of MASLD were 15,018.1 cases (95% UI 13,756.5–16,361.4), annual incidence rates were 608.5 cases (598.8–617.7), and YLDs were 0.5 (0.3–0.8) years. MASLD point prevalence was higher in men than women (15,731.4 vs. 14,310.6 cases per 100,000 population). Prevalence peaked at ages 45–49 for men and 50–54 for women. Kuwait (32,312.2 cases per 100,000 people; 95% UI: 29,947.1–34,839.0), Egypt (31,668.8 cases per 100,000 people; 95% UI: 29,272.5–34,224.7), and Qatar (31,327.5 cases per 100,000 people; 95% UI: 29,078.5–33,790.9) had the highest prevalence rates in 2021. The largest increases in age-standardized point prevalence estimates from 2010 to 2021 were in China (16.9%, 95% UI 14.7%–18.9%), Sudan (13.3%, 95% UI 9.8%–16.7%) and India (13.2%, 95% UI 12.0%–14.4%). MASLD incidence varied with SDI, peaking at moderate SDI levels. Conclusions: MASLD is a global health concern, with the highest prevalence reported in Kuwait, Egypt, and Qatar. Raising awareness about risk factors and prevention is essential in every country, especially in China, Sudan and India, where disease incidence and prevalence are rapidly increasing. Impact and implications: This research provides a comprehensive analysis of the global burden of MASLD, highlighting its rising prevalence and incidence, particularly in countries with varying sociodemographic indices. The findings are significant for both clinicians and policymakers, as they offer critical insights into the regional disparities in MASLD burden, which can inform targeted prevention and intervention strategies. However, the study's reliance on modeling and available data suggests cautious interpretation, and further research is needed to validate these findings in clinical and real-world settings.
KW - Epidemiology
KW - Metabolic dysfunction-associated fatty liver disease
KW - Metabolic dysfunction-associated steatotic liver disease
KW - Non-alcoholic fatty liver disease
UR - https://www.scopus.com/pages/publications/85216484159
U2 - 10.1016/j.jhepr.2024.101271
DO - 10.1016/j.jhepr.2024.101271
M3 - Article
C2 - 39980749
SN - 2589-5559
VL - 7
JO - JHEP Reports
JF - JHEP Reports
IS - 3
M1 - 101271
ER -